Climb Bio (CLYM) Corporate presentation summary

Mission and strategy

• Focused on developing disease-modifying monoclonal antibody (mAb) therapies for immune-mediated diseases, especially those impacting kidney health.

• Leveraging clinically validated B cell targets and proven mAb modalities for indications with clear endpoints and regulatory pathways.

• Targeting expansive commercial opportunities in diseases with high unmet need, including primary membranous nephropathy (PMN), immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and IgA nephropathy (IgAN).

• Anticipating multiple clinical readouts in 2026 across both lead programs.

• Cash runway extends into 2028, supporting advancement through key milestones.

Clinical pipeline and development

• Five clinical studies underway, with initial data expected from all ongoing trials in 2026.

• Budoprutug (anti-CD19 mAb) in development for PMN, ITP, and SLE, with both IV and SC formulations.

• CLYM116 (anti-APRIL mAb) in development for IgAN, with Phase 1 data in healthy volunteers expected mid-2026.

• Budoprutug SC Phase 1 trial dosing completed; data anticipated H1 2026.

• Global and China SLE Phase 1b trials for budoprutug enrolling, with initial data expected H2 2026.

Budoprutug: clinical data and differentiation

• Demonstrated rapid, deep, and durable B cell depletion in PMN, with 100% serologic remission and all patients achieving clinical remission by Week 48 in Phase 1b.

• Well-tolerated safety profile in Phase 1b PMN trial, with no deaths, no dose-limiting toxicities, and no discontinuations due to adverse events.

• Competitive profile in PMN compared to other therapies, with high rates of serologic and clinical remission.

• SC formulation offers potential for at-home administration and broader patient reach.